ADCT Valuation
ADC Therapeutics SA
$
3.290
- Overview
- Forecast
- Valuation
- Earnings
ADCT Relative Valuation
ADCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADCT is overvalued; if below, it's undervalued.
Historical Valuation
ADC Therapeutics SA (ADCT) is now in the Fair zone, suggesting that its current forward PS ratio of 4.85 is considered Fairly compared with the five-year average of -3.89. The fair price of ADC Therapeutics SA (ADCT) is between 2.16 to 3.32 according to relative valuation methord.
Relative Value
Fair Zone
2.16-3.32
Current Price：3.18
Fair
-2.36
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
ADC Therapeutics SA. (ADCT) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -4.08. The thresholds are as follows: Strongly Undervalued below -10.91, Undervalued between -10.91 and -7.49, Fairly Valued between -0.66 and -7.49, Overvalued between -0.66 and 2.75, and Strongly Overvalued above 2.75. The current Forward EV/EBITDA of 0.00 falls within the Overvalued range.
-4.42
EV/EBIT
ADC Therapeutics SA. (ADCT) has a current EV/EBIT of -4.42. The 5-year average EV/EBIT is -3.97. The thresholds are as follows: Strongly Undervalued below -9.22, Undervalued between -9.22 and -6.60, Fairly Valued between -1.35 and -6.60, Overvalued between -1.35 and 1.28, and Strongly Overvalued above 1.28. The current Forward EV/EBIT of -4.42 falls within the Historic Trend Line -Fairly Valued range.
4.85
PS
ADC Therapeutics SA. (ADCT) has a current PS of 4.85. The 5-year average PS is 122.36. The thresholds are as follows: Strongly Undervalued below -1559.88, Undervalued between -1559.88 and -718.76, Fairly Valued between 963.49 and -718.76, Overvalued between 963.49 and 1804.61, and Strongly Overvalued above 1804.61. The current Forward PS of 4.85 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
ADC Therapeutics SA. (ADCT) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.59. The thresholds are as follows: Strongly Undervalued below -17.93, Undervalued between -17.93 and -11.26, Fairly Valued between 2.08 and -11.26, Overvalued between 2.08 and 8.75, and Strongly Overvalued above 8.75. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-3.08
P/FCF
ADC Therapeutics SA. (ADCT) has a current P/FCF of -3.08. The 5-year average P/FCF is -4.08. The thresholds are as follows: Strongly Undervalued below -12.79, Undervalued between -12.79 and -8.43, Fairly Valued between 0.27 and -8.43, Overvalued between 0.27 and 4.63, and Strongly Overvalued above 4.63. The current Forward P/FCF of -3.08 falls within the Historic Trend Line -Fairly Valued range.
ADC Therapeutics SA (ADCT) has a current Price-to-Book (P/B) ratio of -1.75. Compared to its 3-year average P/B ratio of -1.05 , the current P/B ratio is approximately 67.54% higher. Relative to its 5-year average P/B ratio of 2.26, the current P/B ratio is about -177.53% higher. ADC Therapeutics SA (ADCT) has a Forward Free Cash Flow (FCF) yield of approximately -37.03%. Compared to its 3-year average FCF yield of -73.40%, the current FCF yield is approximately -49.55% lower. Relative to its 5-year average FCF yield of -50.08% , the current FCF yield is about -26.07% lower.
-1.75
P/B
Median3y
-1.05
Median5y
2.26
-37.03
FCF Yield
Median3y
-73.40
Median5y
-50.08
Competitors Valuation Multiple
The average P/S ratio for ADCT's competitors is 7.33, providing a benchmark for relative valuation. ADC Therapeutics SA Corp (ADCT) exhibits a P/S ratio of 4.85, which is -33.86% above the industry average. Given its robust revenue growth of 8.21%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ADCT decreased by 1.59% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -209.90 to -300.68.
The secondary factor is the Revenue Growth, contributed 8.21%to the performance.
Overall, the performance of ADCT in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
HNVR
Hanover Bancorp Inc
22.250
USD
-0.22%
SPKL
Spark I Acquisition Corp
10.983
USD
+0.30%
CLAR
Clarus Corp
3.480
USD
-0.57%
NKTX
Nkarta Inc
2.100
USD
0.00%
TOYO
TOYO Co., Ltd
6.180
USD
+6.55%
FLL
Full House Resorts Inc
3.550
USD
-0.84%
PLL
Piedmont Lithium Inc
7.310
USD
-9.79%
MNPR
Monopar Therapeutics Inc
36.210
USD
+6.72%
STXS
Stereotaxis Inc
2.710
USD
0.00%
FAQ
Is ADC Therapeutics SA (ADCT) currently overvalued or undervalued?
ADC Therapeutics SA (ADCT) is now in the Fair zone, suggesting that its current forward PS ratio of 4.85 is considered Fairly compared with the five-year average of -3.89. The fair price of ADC Therapeutics SA (ADCT) is between 2.16 to 3.32 according to relative valuation methord.
What is ADC Therapeutics SA (ADCT) fair value?
How does ADCT's valuation metrics compare to the industry average?
What is the current P/B ratio for ADC Therapeutics SA (ADCT) as of Sep 03 2025?
What is the current FCF Yield for ADC Therapeutics SA (ADCT) as of Sep 03 2025?
What is the current Forward P/E ratio for ADC Therapeutics SA (ADCT) as of Sep 03 2025?